MASTL

Across TCGA pan-cancer cohorts, MASTL Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MASTL data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MASTL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MASTL expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

SKCM, LIHC, and UCEC are the cancer types where MASTL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.029	0.613	<.001	17	view →
LIHC	OS	Median	III,IV	0.118	0.615	.003	6	view →
UCEC	DFS	Median	All	0.933	0.608	.011	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
STAD	DFS	Median	IV	1.000	0.284	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MASTL–SKCM (DFS)

Open the SKCM breakdown →